PHARMACOTHERAPEUTIC FOLLOW-UP OF PATIENTS WHO USE TENOFOVIR DISOPROXIL FUMARATE IN PRE-EXPOSURE TO HIV

Abstract

The Human Immunosuficiency Virus (HIV) is a serious public health problem worldwide. It infects the cells of the immune system, which can lead to the development of Acquired Immunodeficiency Syndrome (AIDS). Pre-Exposure Prophylaxis (PrEP) is the use of antiretroviral drugs before exposure to the HIV virus in order to reduce the risk of infection. The article aims to carry out an integrative review of the theme: pharmacotherapeutic follow-up of patients who use tenofovir disoproxil fumarate in pre-exposure to HIV. The databases used to search for publications were: Scielo (Scientific Electronic Library Online), LILACS (Latin American and Caribbean Literature in Health Sciences), LA Referência (Federated Network of Institutional Repositories of Scientific Publications) and PubMed, the search took place from January 2023 to July 2023. The descriptors used to search for publications were: “HIV”, “pharmacological treatment”, “PrEP”, “tenofovir disoproxil fumarate” and “pharmaceutical care”. Thirteen bibliographic references were cataloged, which met the inclusion and exclusion criteria. Currently, only 28.7 million patients are using HIV treatment, one of the reasons why the number is still below the desired level is because not all infected people are aware of their diagnosis. PrEP prophylaxis is recommended for populations at risk and it plays an important role in reducing the risk of acquiring HIV. The institution of PrEP in the Brazilian public health service demonstrated an adherence rate close to 80% in certain populations. In addition, the presence of the pharmacist is of great importance for guiding this patient regarding the correct use of PrEP. We conclude that the use of tenofovir disoproxil fumarate by the patient without proper guidance from a qualified professional, in this case the pharmacist, can lead to the appearance of adverse events, exposing the patient to therapeutic failures and the risk of contracting the HIV.